.png)
Goal
- Identify new cell-based immune biomarkers associated with response, combination regimens, and dose
- Validate and complement results from existing genomic sequencing data sets
- Track the impact of their drug on the entire immune system over time
Approach with Teiko
- Verify 10 additional markers on top of Teiko’s 33-marker CyTOF backbone that are associated with the drug's mechanism of action
- Profile 24 cryopreserved Peripheral Blood Mononuclear Cells (PBMCs) from 8 patients with liver cancer with custom 43-marker CyTOF assessing 800+ immune cell populations and functional marker subsets per sample
- Runtime for project: ~6 weeks
Results
- We identified novel immune cell biomarkers that correlated with treatment response
- Detected dose- and combo treatment-dependent changes to the immune system
- Confirmed genomic sequencing findings with protein-level analysis
- Developed a custom 43-marker CyTOF panel for PBMC profiling
- Delivered statistically verified results in an interactive web dashboard, enabling deeper insights with PCA, UMAP, and heatmaps.
Who Cares?
- This drug developer successfully tested multiple hypotheses simultaneously from a single experiment—both validating existing datasets and identifying novel biomarkers.
- Moreover, the team could disaggregate the pharmacodynamic impact of their own drug with a combination drug.
- The researchers were able to assess how their drug shaped immune responses alone and in combination with a checkpoint inhibitor, distinguishing their drug's effects from the checkpoint inhibitor.
- Instead of waiting 3–6 months, they received a verified custom panel and cytometry results in 6 weeks with Teiko, enabling them to move to the next stage of their clinical program faster.
